Q3 2022 Results
Company overview
Financial review
2022 priorities
Appendix
References
Strong performance of EntrestoⓇ, KesimptaⓇ, Kisqali ®, PluvictoⓇ
Q3 sales1
Sales
Growth vs. PY
USD million
USD million
Entresto
sacubitril/valsartan
1,135
Kesimpta
289
(ofatumumab)
KISQALI
327
95
ribociclib
80
80
PLUVICTO™
Ⓒ SCEMBLIX*
41
41
(asciminib)
Tafinlar. Mekinist.
450
33
decent
LEQVIO®
34
29
Cosentyx
1,274
27
(secukinumab)
PIQRAY
(alpelisib) tablets
MAYZENT.
103
21
94
18
(siponimod) tablets
LUTATHERA
132
12
Growth vs. PY
CC
211
31%
180
172%
49%
nm
nm
16%
nm
7%
26%
29%
15%
Constant currencies (cc) is a non-IFRS measure; explanation of non-IFRS measures can be found on page 49 of Condensed Interim Financial Report. Unless otherwise noted, all growth rates refer to same period in PY.
nm not meaningful 1. Innovative Medicines division.
5 Investor Relations | Q3 2022 Results
1
GROWTH
✓ NOVARTIS | Reimagining MedicineView entire presentation